Sinopharm Trust Medical Devices Completes IPO Tutoring Inspection, Prepares for Listing with Multi-Hundred-Million-Yuan Financing and Innovative Cardiovascular Product Pipeline

Recently, the official website of the CSRC showed that Salubris Medtech (hereinafter referred to as "Salubris Medtech") completed IPO coaching acceptance. The coaching institution was China International Capital Corporation Limited, and the dispatched institution was Shenzhen CSRC Bureau.

Source of the image: Official website of the CSRC

Public information shows that Salubris Medtech is an innovative cardiovascular and cerebrovascular medical device platform under Salubris Pharmaceuticals. The company has developed multiple globally and China-first vascular implantation and interventional devices through self-research, acquisitions, and product rights introductions in areas such as neurointervention, cardiovascular intervention, peripheral vascular diseases, structural heart diseases, electrophysiology, and hypertension. It provides comprehensive solutions spanning diagnosis, prevention, treatment, and rehabilitation for the above-mentioned cardiovascular and cerebrovascular conditions. Salubris Medtech has successfully acquired and integrated companies including Suzhou Hengchen Medical, Beijing Yalun Biotech, and Shenzhen Keyidun Biotech; invested in and obtained core product rights from Switzerland's Med Alliance and the U.S.-based Mercator; and strategically invested in Goldschmidt Biotech, Sichuan Jinjiang Electronics, and Shanghai Yueguang Medical, accumulating robust in-house and external product development and commercialization capabilities as a mature medical device platform.

Salubris Medtech's core products include the Maurora vertebral artery stent in the field of neurointervention, which is the world's first rapamycin-eluting stent for vertebral artery stenosis. It received NMPA approval at the end of 2020 and achieved remarkable commercial milestones in 2021. In cardiovascular intervention, the rapamycin-coated drug balloon featuring globally leading drug-coating technology is currently in the registration clinical stage and is expected to become one of the first rapamycin drug balloons to be marketed in China. The LAMax LAAC left atrial appendage occluder for structural heart disease is the earliest product in China and globally to conduct randomized controlled trials with Boston Scientific’s widely-used WATCHMAN™. It has now entered the registration application stage. In peripheral vascular interventions, multiple innovative products are also under development, including vena cava filters, iliac vein stents, drug-eluting stents for lower limbs, and rapamycin peripheral drug balloons. In the coming years, the company will continue to increase its investment in innovation, expand its product pipeline, and enhance its commercialized product portfolio.

At the same time, Salubris Medtech has completed the integration of clinical operation resources, the construction of an intensive production base, and the establishment of a sales platform with in-depth coverage across China. The company will always adhere to addressing clinical needs, centering on patients, promoting evidence-based medicine, advancing independent innovation and R&D alongside the introduction of global innovative technologies. It will form a strategic synergy with Salubris Pharmaceuticals to build a globalized, innovative cardiovascular and cerebrovascular medical device platform enterprise that integrates R&D, clinical trials, production, and commercialization.

According to the PharmaCube InvestGo investment and financing database, Salubris Medtech has previously completed two rounds of financing worth hundreds of millions of yuan.